 Company Information |
Listed in:
Research & Development in the Physical, Engineering & Life Sciences
Pharmaceutical & Medicine Manufacturing
Testing Laboritories
Description:
MethylGene is a publicly-traded biopharmaceutical company focused on the discovery, development and commercialization of novel therapeutics in cancer and infectious diseases. We intend to exploit our HDAC inhibitor technology in other diseases, such as diabetes, inflammation, fungal infections and neurodegenerative disorders. Two cancer product candidates are currently in clinical trials: MGCD0103, partnered with Pharmion Corporation and Taiho Pharmaceutical Co., Ltd., and MG98, partnered with MGI Pharma, Inc. MethylGene has an exclusive license agreement with Merck & Co. for the development and commercialization of small molecule beta-lactamase inhibitors to overcome antibiotic resistance. MethylGene has partnered its non-oncology HDAC program for neurodegenerative diseases with EnVivo Pharmaceuticals. MethylGene has a portfolio of preclinical programs for its multi-targeted kinase and histone deacetylase (HDAC) inhibitors for both oncology and non-oncology indications, and continues to seek partnering opportunities in these areas.
MethylGene has received $41.9 million of investment and funding
from Venture Capitalists, including a $4.8 million award from
Technology Partnerships Canada. The company has also raised
US$17.2 million in equity and upfront payments from their
partners.
|
| Products |
 |
Mgcd0103 Hdac Inhibitor In Clinical Trials For Oncology
|
|
| Services |
 |
Pharmaceutical Products
|
|
|
 |
|